---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008779"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:19:57.238926+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA

## Summary
- ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).
- EHA poster presentation on June 14, 2024 (6:00 PM CEST, Madrid, abstract #P536).
- Interim Phase 2 data for prexigebersen (BP1001) plus decitabine/venetoclax in AML show it's well-tolerated with compelling efficacy.
- Data from newly diagnosed and refractory/relapsed cohorts both exceeded outcomes with frontline therapy.
- No specific numerical results were disclosed in the press releases.

## SEC filing metadata
- accession: 0001558370-24-008779
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/0001558370-24-008779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/bpth-20240523x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008779
- JSON: https://secwatch.observer/filing/0001558370-24-008779.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.